Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    Anti-LAG-3 Monoclonal Antibody (BMS-986016) Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) | Advanced Solid Tumors
Previous Study | Return to List | Next Study

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02966548
Recruitment Status : Active, not recruiting
First Posted : November 17, 2016
Last Update Posted : November 1, 2021
Sponsor:
Collaborator:
Ono Pharmaceutical Co. Ltd
Information provided by (Responsible Party):
Bristol-Myers Squibb

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : September 8, 2022
Estimated Study Completion Date : September 9, 2022